Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DI-Leu16-IL2
- Development stage
- Discontinued
- Lead developer
- Alopexx Oncology
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
DI-Leu16-IL2 is a recombinant fusion protein composed of a de-immunized and humanized anti-CD20 monoclonal antibody (Leu16) fused to the human cytokine interleukin-2 (IL-2). It is being developed as an immuno-oncology therapy for blood cancers, particularly B-cell lymphomas. The drug works by targeting CD20, a protein overexpressed on the surface of B-cells in various cancers. The antibody portion binds to CD20-expressing tumor cells, inducing antibody-dependent cell-mediated cytotoxicity (ADCC), while the IL-2 portion stimulates natural killer (NK) cells and T-cells to enhance immune-mediated killing of cancer cells. This dual mechanism results in more potent antitumor activity than either component alone or their combination as separate agents[1][2][5].
- Other names
- di-leu16-il2 immunocytokinedi-leu-16-il2 immunocytokinedi-leu 16-il2 immunocytokine
02
Targets
CD20 (B-lymphocyte antigen CD20)IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on DI-Leu16-IL2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DI-Leu16-IL2.